Eam Global Investors LLC Fate Therapeutics Inc Transaction History

Eam Global Investors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$13.39 - $20.73 $666,768 - $1.03 Million	-49,796 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$15.47 - $22.5 $642,561 - $934,560	-41,536 Reduced 45.48%	49,796 $773,000
Q1 2019 May 10, 2019	SELL	$13.15 - $18.71 $155,077 - $220,647	-11,793 Reduced 11.44%	91,332 $1.61 Million
Q3 2018 Nov 08, 2018	BUY	$8.75 - $16.29 $220,815 - $411,094	25,236 Added 32.4%	103,125 $1.68 Million
Q1 2018 Jun 04, 2018	BUY	$6.3 - $13.77 $490,700 - $1.07 Million	77,889 New	77,889 $760,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $174M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.